Stockscreener 앱 받기
31.86
22.50%
5.81
Cassava Sciences Inc 주식(SAVA)의 최신 뉴스
January 2025 Options Now Available For Cassava Sciences (SAVA) - Nasdaq
Is Cassava Sciences (SAVA) Outperforming Other Medical Stocks This Year? - MSN
Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer - citybiz
Cassava Sciences, Inc. Appoints Freda Nassif as Chief Commercial Officer - Marketscreener.com
Cassava Sciences stock up on Alzheimer’s update (SAVA:NASDAQ) - Seeking Alpha
What Makes Cassava Sciences (SAVA) a New Buy Stock - MSN
A High-potential Bull Put Strategy on Cassava Sciences - MSN
A High-Potential Bull Put Strategy On Cassava Sciences - Barchart
Cassava Sciences Inc (SAVA-Q) QuotePress Release - The Globe and Mail
Anavex, Cassava Sciences, Panax Ginseng, And Long-Term Treatment Of Alzheimer's Disease - Seeking Alpha
How To Trade (SAVA) - Stock Traders Daily
Cassava Sciences, Inc. (NASDAQ:SAVA) Q3 2024 Earnings Call Transcript - Insider Monkey
Cassava Sciences (NASDAQ:SAVA) Issues Quarterly Earnings Results - MarketBeat
Cassava Sciences (NASDAQ:SAVA) Given "Buy" Rating at HC Wainwright - MarketBeat
Cassava Sciences Q3 2024 Earnings Preview - MSN
Friday's Top 5 Trending Stocks: What's The Scoop On GameStop, SoFi, Tesla? - Benzinga
Another U.S. biotech based on Chinese science - STAT
Cassava Sciences: With Almost Half The Float Shorted, Results Could Be Interesting - Seeking Alpha
Cassava Sciences nears Alzheimer's drug trial results By Investing.com - Investing.com Canada
Cassava Sciences’ Q3 2024: Financials and Alzheimer’s Trials Progress - TipRanks
Cassava Sciences: Pivotal Alzheimer’s Data May Push Stock Toward Book Value (SAVA) - Seeking Alpha
Cassava Q3 Earnings Review: It Feels Like The End May Be Nigh (NASDAQ:SAVA) - Seeking Alpha
Looking At Cassava Sciences's Recent Unusual Options Activity - Benzinga
Cassava Sciences nears Alzheimer's drug trial results - Investing.com India
Cassava Sciences stock in focus after earnings (SAVA:NASDAQ) - Seeking Alpha
Cassava Sciences Reports Q3 2024 Financial and Operating Results - The Manila Times
Cassava Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Cassava Sciences (NASDAQ:SAVA) Trading Down 5.8%Should You Sell? - MarketBeat
Unpacking the Latest Options Trading Trends in Cassava Sciences - Benzinga
Analysts Believe Cassava Sciences Now Has 300% Upside From Here - MSN
Cassava Sciences (SAVA) Scheduled to Post Earnings on Thursday - MarketBeat
Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024 - GlobeNewswire
International Assets Investment Management LLC Makes New Investment in Cassava Sciences, Inc. (NASDAQ:SAVA) - MarketBeat
Institutions along with individual investors who hold considerable shares inCassava Sciences, Inc. (NASDAQ:SAVA) come under pressure; lose 6.7% of holdings value - Yahoo Finance
Long Term Trading Analysis for (SAVA) - Stock Traders Daily
HC Wainwright & Co. Upgrades Cassava Sciences (SAVA) - MSN
Cassava Sciences Options Trading: A Deep Dive into Market Sentiment - Benzinga
Institutions profited after Cassava Sciences, Inc.'s (NASDAQ:SAVA) market cap rose US$72m last week but individual investors profited the most - Simply Wall St
(SAVA) Proactive Strategies - Stock Traders Daily
Cassava Sciences, Inc. (SAVA): Jim Cramer Says Eli Lilly Has The Edge - Insider Monkey
Cassava Sciences (NASDAQ:SAVA) Trading 5.1% HigherWhat's Next? - MarketBeat
1.80%
0.42%
자본화:
|
볼륨(24시간):